Selinexor

Key Product Details

Product Description

Selinexor is an inhibitor of the exportin 1 (XPO1/CRM1) nuclear exporter. Shows selectivity for TNBC over ER-positive breast cancer cell lines (IC₅₀ values are 11-550 nM and >1000 nM, respectively), and reduces growth of xenografts. Inhibits growth of thyroid cancer cell lines (IC₅₀ = 150-500 nM), potentiates the anti-tumor effects of Olaparib (Cat. No. 7579) in ovarian cancer and breast cancer. Also a potent inhibitor of SARS-CoV-2 replication in vitro (EC₅₀ = 10 nM) and downregulates the production of pro-inflammatory cytokines including TNF-α and IL-6.

Product Specifications for Selinexor

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Selinexor

The following data is based on the product molecular weight 443.31.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.26 mL	11.28 mL	22.56 mL
5 mM	0.45 mL	2.26 mL	4.51 mL
10 mM	0.23 mL	1.13 mL	2.26 mL
50 mM	0.05 mL	0.23 mL	0.45 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Marijon Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status. Oncotarget. 2021 PMID: 34504648
• Kashyap Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo. Antiviral Res. 2021 PMID: 34157321
• Arango Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 PMID: 28810913

Product Documents for Selinexor